Workshop on Monoclonal Antibodies in Cancer
Workshop Main Page | Highlights | Program Purpose | Presentations Slides & Schedule
| Faculty
Preliminary Program | Photos
| FacultyPreliminary Program | Photos
|
October 1, 2010 Hyatt Regency Washington on Capitol Hill Washington, D.C. |
Organizers Glenn Dranoff, MD ~ Dana-Farber Cancer Institute Ira Mellman, PhD ~ Genentech, Inc. George J. Weiner, MD ~ University of Iowa |
To view slides from a presenter click on the 
icon.
Approximately 90 scientists from academia, government and industry participated in our Workshop, which included interactive panel discussions and presentations delivered by 10 prominent researchers who are investigating the use of monoclonal antibodies (mAbs) in cancer. Faculty discussed issues surrounding the development and clinical application of mAbs in oncology, including the current understanding of a variety of molecular targets, mechanisms of action, mAb engineering, mAb derivatives, immunomodulating mAbs and the clinical use of mAbs.
Presentations were organized under the following topics:
- Tumor-Targeting Antibodies
- Immunomodulatory Antibodies
- Investigating Antibodies as “Vaccines”
- Antibody Engineering
SITC/iSBTc member Paul Sondel, MD, PhD presented positive final results from a Phase III randomized trial that involved application of anti-GD2 antibody in the treatment of neuroblastoma. The results were published the day before the Workshop in the New England Journal of Medicine adding to the excitement at the session. A summary of the study is available online.